Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events

被引:9
作者
Singh, Pratibha [1 ]
Goncalves, Isabel [1 ,2 ]
Tengryd, Christoffer [1 ]
Nitulescu, Mihaela [1 ]
Persson, Ana F. [1 ]
To, Fong [1 ]
Bengtsson, Eva [1 ]
Volkov, Petr [3 ]
Orho-Melander, Marju [1 ]
Nilsson, Jan [1 ]
Edsfeldt, Andreas [1 ,2 ,4 ]
机构
[1] Lund Univ, Clin Res Ctr, Dept Clin Sci, Malmo, Sweden
[2] Skane Univ Hosp, Dept Cardiol, Lund, Sweden
[3] Lund Univ, Diabet Ctr, Bioinformat Unit, Malmo, Sweden
[4] Lund Univ, Wallenberg Ctr Mol Med, Malmo, Sweden
基金
瑞典研究理事会;
关键词
Carotid stenosis; Atherosclerosis; Oxidized low-density lipoproteins; Diabetes mellitus; LOW-DENSITY-LIPOPROTEIN; TYPE-2; DIABETES-MELLITUS; ATHEROSCLEROTIC PLAQUES; GLYCEMIC CONTROL; PARTICLE-SIZE; CAROTID PLAQUES; HEART-DISEASE; EXPRESSION; RISK; CALCIFICATION;
D O I
10.1186/s12933-020-01189-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Type 2 diabetes (T2D) patients are at a greater risk of cardiovascular events due to aggravated atherosclerosis. Oxidized LDL (oxLDL) has been shown to be increased in T2D plaques and suggested to contribute to plaque ruptures. Despite intensified statin treatment during the last decade the higher risk for events remains. Here, we explored if intensified statin treatment was associated with reduced oxLDL in T2D plaques and if oxLDL predicts cardiovascular events, to elucidate whether further plaque oxLDL reduction would be a promising therapeutic target. Methods Carotid plaque OxLDL levels and plasma lipoproteins were assessed in 200 patients. Plaque oxLDL was located by immunohistochemistry. Plaque cytokines, cells and scavenger receptor gene expression were quantified by Luminex, immunohistochemistry and RNA sequencing, respectively. Clinical information and events during follow-up were obtained from national registers. Results Plaque oxLDL levels correlated with markers of inflammatory activity, endothelial activation and plasma LDL cholesterol (r = 0.22-0.32 and p <= 0.01 for all). T2D individuals exhibited lower plaque levels of oxLDL, sLOX-1(a marker of endothelial activation) and plasma LDL cholesterol (p = 0.001, p = 0.006 and p = 0.009). No increased gene expression of scavenger receptors was identified in T2D plaques. The lower oxLDL content in T2D plaques was associated with a greater statin usage (p = 0.026). Supporting this, a linear regression model showed that statin treatment was the factor with the strongest association to plaque oxLDL and plasma LDL cholesterol (p < 0.001 for both). However, patients with T2D more frequently suffered from symptoms and yet plaque levels of oxLDL did not predict cardiovascular events in T2D (findings are summarized in Fig. 1a). Conclusions This study points out the importance of statin treatment in affecting plaque biology in T2D. It also implies that other biological components, beyond oxLDL, need to be identified and targeted to further reduce the risk of events among T2D patients receiving statin treatment.
引用
收藏
页数:12
相关论文
共 46 条
  • [1] Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
    Beckman, JA
    Creager, MA
    Libby, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19): : 2570 - 2581
  • [2] Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes
    Berneis, K
    Jeanneret, C
    Muser, E
    Felix, B
    Miserez, AR
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (02): : 227 - 234
  • [3] Large triglyceride-rich lipoproteins from fasting patients with type 2 diabetes activate platelets
    Boulet, M. M.
    Cheillan, D.
    Di Filippo, M.
    Buisson, C.
    Michalski, M-C
    Moulin, P.
    Calzada, C.
    [J]. DIABETES & METABOLISM, 2020, 46 (01) : 54 - 60
  • [4] Morphologic findings of coronary atherosclerotic plaques in diabetics - A postmortem study
    Burke, AP
    Kolodgie, FD
    Zieske, A
    Fowler, DR
    Weber, DK
    Varghese, PJ
    Farb, A
    Virmani, R
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (07) : 1266 - 1271
  • [5] The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques - Role of glycemic control
    Cipollone, F
    Iezzi, A
    Fazia, M
    Zucchelli, M
    Pini, B
    Cuccurullo, C
    De Cesare, D
    De Blasis, G
    Muraro, R
    Bei, R
    Chiarelli, F
    Schmidt, AM
    Cuccurullo, F
    Mezzetti, A
    [J]. CIRCULATION, 2003, 108 (09) : 1070 - 1077
  • [6] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [7] The carotid plaque as paradigmatic case of site-specific acceleration of aging process: The microRNAs and the inflammaging contribution
    Collura, Salvatore
    Morsiani, Cristina
    Vacirca, Andrea
    Fronterre, Sara
    Ciavarella, Carmen
    Vasuri, Francesco
    D'Errico, Antonia
    Franceschi, Claudio
    Pasquinelli, Gianandrea
    Gargiulo, Mauro
    Capri, Miriam
    [J]. AGEING RESEARCH REVIEWS, 2020, 61
  • [8] Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization
    Crisby, M
    Nordin-Fredriksson, G
    Shah, PK
    Yano, J
    Zhu, J
    Nilsson, J
    [J]. CIRCULATION, 2001, 103 (07) : 926 - 933
  • [9] Modulation of the inflammatory process by statins
    Crisby, M
    [J]. DRUGS OF TODAY, 2003, 39 (02) : 137 - 143
  • [10] The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin
    Draude, G
    Hrboticky, N
    Lorenz, RL
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 57 (04) : 383 - 386